{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:34:33Z","timestamp":1776094473953,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,7]]},"DOI":"10.7759\/cureus.71007","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T15:27:17Z","timestamp":1728314837000},"source":"Crossref","is-referenced-by-count":1,"title":["Herpes Zoster and Venous Thromboembolism Following Upadacitinib Treatment for Severe Atopic Dermatitis"],"prefix":"10.7759","author":[{"given":"Kawaiola Cael","family":"Aoki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Burnette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Bartos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-8-5","article-title":"Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib","volume":"9","author":"Nezamololama N","year":"2020","unstructured":"Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020, 9:10.7573\/dic.2020-8-5","journal-title":"Drugs Context"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop KL","year":"2022","unstructured":"Winthrop KL, Nash P, Yamaoka K, et al.. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Ann Rheum Dis. 2022, 81:206-13. 10.1136\/annrheumdis-2021-220822","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen SB","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al.. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021, 80:304-11. 10.1136\/annrheumdis-2020-218510","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel JF","year":"2018","unstructured":"Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis. 2018, 24:2173-82. 10.1093\/ibd\/izy150","journal-title":"Inflamm Bowel Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2000.tb02599.x","article-title":"IL-12, IFN-gamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella","volume":"44","author":"Torigo S","year":"2000","unstructured":"Torigo S, Ihara T, Kamiya H. IL-12, IFN-gamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella. Microbiol Immunol. 2000, 44:1027-31. 10.1111\/j.1348-0421.2000.tb02599.x","journal-title":"Microbiol Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi K","year":"2009","unstructured":"Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009, 228:273-87. 10.1111\/j.1600-065X.2008.00754.x","journal-title":"Immunol Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610253113","article-title":"Network pharmacology of JAK inhibitors","volume":"113","author":"Moodley D","year":"2016","unstructured":"Moodley D, Yoshida H, Mostafavi S, et al.. Network pharmacology of JAK inhibitors. Proc Natl Acad Sci U S A. 2016, 113:9852-7. 10.1073\/pnas.1610253113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.11.001","article-title":"A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis","volume":"6","author":"Katoh N","year":"2022","unstructured":"Katoh N, Ohya Y, Murota H, et al.. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis. JAAD Int. 2022, 6:27-36. 10.1016\/j.jdin.2021.11.001","journal-title":"JAAD Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14890","article-title":"Novel agents for atopic dermatitis in patients over 50\u2009years of age: a case series","volume":"34","author":"Kiely L","year":"2021","unstructured":"Kiely L, Bowe S, O'Connor C, Bennett M, Bourke J, Murphy M. Novel agents for atopic dermatitis in patients over 50\u2009years of age: a case series. Dermatol Ther. 2021, 34:e14890. 10.1111\/dth.14890","journal-title":"Dermatol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander V","year":"2023","unstructured":"Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. 2023, 82:189-97. 10.1136\/ard-2022-223050","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223916","article-title":"Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme","volume":"82","author":"Fleischmann R","year":"2023","unstructured":"Fleischmann R, Curtis JR, Charles-Schoeman C, et al.. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023, 82:1130-41. 10.1136\/ard-2023-223916","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials","volume":"158","author":"Simpson EL","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, et al.. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022, 158:404-13. 10.1001\/jamadermatol.2022.0029","journal-title":"JAMA Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00798-0","article-title":"Long-term effectiveness and safety of upadacitinib for atopic dermatitis\u00a0in a real-world setting: an interim analysis through 48 weeks of observation","volume":"24","author":"Chiricozzi A","year":"2023","unstructured":"Chiricozzi A, Ortoncelli M, Schena D, et al.. Long-term effectiveness and safety of upadacitinib for atopic dermatitis\u00a0in a real-world setting: an interim analysis through 48 weeks of observation. Am J Clin Dermatol. 2023, 24:953-61. 10.1007\/s40257-023-00798-0","journal-title":"Am J Clin Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/277761-herpes-zoster-and-venous-thromboembolism-following-upadacitinib-treatment-for-severe-atopic-dermatitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T15:27:19Z","timestamp":1728314839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/277761-herpes-zoster-and-venous-thromboembolism-following-upadacitinib-treatment-for-severe-atopic-dermatitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.71007","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,7]]}}}